The Metabolic Syndrome in Polycystic Ovary Syndrome

Essah, Paulina A.; Wickham, Edmond P.; Nestler, John E.

doi:10.1097/grf.0b013e31802f3547

Cited by 79 publications

(30 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 PCOS is associated with metabolic abnormalities, such as dyslipidemia, obesity, and glucose intolerance, which are also components of the metabolic syndrome (MS). 2 The prevalence of MS in adult premenopausal women with PCOS is approximately 40%. 3 There is a growing appreciation that adolescents are at increasing risk for type 2 diabetes mellitus and MS since the prevalence of obesity is increasing in this population.…”

Section: Introductionmentioning

confidence: 99%

Association Between Polycystic Ovarian Syndrome, Overweight, and Metabolic Syndrome in Adolescents

Rahmanpour¹,

Jamal²,

Mousavinasab³

et al. 2012

Journal of Pediatric and Adolescent Gynecology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Association Between Polycystic Ovarian Syndrome, Overweight, and Metabolic Syndrome in Adolescents

Rahmanpour¹,

Jamal²,

Mousavinasab³

et al. 2012

Journal of Pediatric and Adolescent Gynecology

View full text Add to dashboard Cite

“…Other associated conditions are increased inflammation, vascular dysfunction, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome, sleep apnea and some types of cancer and dementia. 16,17,18,19,20,21,22,23,24 Obesity is commonly viewed as the cause of metabolic syndrome. However, while obesity is highly correlated with the condition, we (and others) suggest that it is the expansion of adipose stores beyond a person's individual storage capacity, 25,26 driven by and in conjunction with hyperinsulinaemia because of the overconsumption of processed dietary carbohydrates in the setting of a Western diet -so prevalent in modern society -that drives this disease process.…”

Section: Metabolic Syndrome As Pre-diabetesmentioning

confidence: 99%

A low-carbohydrate survey: Evidence for sustainable metabolic syndrome reversal

Cucuzzella

Tondt

Dockter

et al. 2017

JMH

View full text Add to dashboard Cite

Background: Metabolic syndrome has become a significant problem, with the American Diabetes Association estimating the cost of diabetes and pre-diabetes in the United States alone to be $322 billion per year. Numerous clinical trials have demonstrated the efficacy of low-carbohydrate diets in reversing metabolic syndrome and its associated disorders.Aim: This study was designed to examine how voluntary adherents to a low-carbohydrate diet rate its effectiveness and sustainability using an online survey.Setting and methods: The 57-question survey was administered online and shared internationally via social media and ‘low-carb’ communities. Where appropriate, chi-squared tests and paired t-tests were used to analyse the responses.Results: There were 1580 respondents. The majority of respondents had consumed less than 100 g of carbohydrates per day for over a year, typically for reasons of weight loss or disease management. There was a reported decrease in waist circumference and weight with a simultaneous decrease in hunger and increase in energy level. Of those who provided laboratory values, the majority saw improvements in their HbA1c, blood glucose measurements, and lipid panel results. There was a reduction in usage of various medications, and 25% reported medication cost savings, with average monthly savings of $288 for those respondents. In particular, the usage of pain relievers and anti-inflammatories dropped with a simultaneous decreased rating of pain and increase in mobility.Conclusion: We conclude that low-carbohydrate diets are a sustainable method of metabolic syndrome reversal in a community setting.

show abstract

“…The progressive nature of the metabolic component of the syndrome is clearly demonstrated by a statistically significant deterioration of insulin sensitivity and body weight as demonstrated in the control group. There is consistent evidence in the literature that the metabolic syndrome is associated, later in life, with a high risk of developing type 2 diabetes mellitus, cardiovascular disease and mortality rate [13][14][15]. Taking necessary measures, at such an early phase of the disease, can have profound benefits on the quality of life of these women, as well as on the general economic burden of the healthcare services [16].…”

Section: Discussionmentioning

confidence: 95%

Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24month follow up period

Maghraby

Nafee

Guiziry

et al. 2015

Middle East Fertility Society Journal

View full text Add to dashboard Cite

Objective: To compare metformin and combined oral contraceptive pill (COC) effects over 24 months in adolescent PCOS. Design: Randomized controlled study. Setting: Alexandria ICSI centre. Patients: 117 adolescent girls with PCOS, were randomized to: group A (n = 40): metformin, group B (n = 40): COC, and group C (n = 39): control. Interventions: Group A: received metformin, group B: received combined oral contraceptives. Main outcome measures: Improvement in cycle rhythm and hirsutism. Results: In group B a significant decline in serum testosterone reached the lowest value by the end of the second year (0.7 ± 0.2 versus 1.3 ± 0.5 lg/ml). By the end of the study, group A showed a significant decline in fasting (18.6 ± 3.0-10.0 ± 3.0 lIU/ml) and after-load insulin levels (126 ± 43-64 ± 15 lIU/ml) with a significant rise in glucose/insulin ratio (GIR) from 4.1 ± 0.3 to 4.6 ± 0.5. Group B showed a significant rise in fasting and after-load insulin (from 15.0 ± 3.0 lIU/ml and 103.0 ± 91.0 lIU/ml to 19.0 ± 4.0 and 187.0 ± 22.0 lIU/ml, respectively) and GIR dropped significantly from 4.4 ± 0.2 to 3.1 ± 0.3. Metformin was associated with a significant loss of weight from 87.0 ± 6.0 to 72.0 ± 0.5 kg while COC was associated with a non-significant gain in weight (from 84.0 ± 6.0 to 91.0 ± 9.0 kg). Conclusions: Metformin and COC have comparable therapeutic effectiveness on cycle regularity and hirsutism. Metformin was associated with a significant improvement in met-* Corresponding author at

show abstract

The Metabolic Syndrome in Polycystic Ovary Syndrome

Cited by 79 publications

References 109 publications

Association Between Polycystic Ovarian Syndrome, Overweight, and Metabolic Syndrome in Adolescents

Association Between Polycystic Ovarian Syndrome, Overweight, and Metabolic Syndrome in Adolescents

A low-carbohydrate survey: Evidence for sustainable metabolic syndrome reversal

Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24month follow up period

Contact Info

Product

Resources

About